October 8, 2014
LEWISVILLE, TX and CLEVELAND, OH – med fusion, an integrated molecular center of excellence and clinical trials service organization and GenomOncology, an Ohio based genomics technology and services provider, today announced a partnership to optimize treatment strategies based on the patient’s disease state and tumor profile. The companies believe that GenomOnoclogy’s proprietary technology platform, the GO Clinical WorkbenchTM, and support services will complement med fusion’s expanded solid tumor disease-specific panels and deliver a comprehensive laboratory report detailing relevant drug and clinical trial options.
med fusion’s solid tumor menu expansion is anticipated early Q3, 2014 with the launch of disease specific panels including NSCLC (Non Small Cell Lung Cancer) and CRC (Colorectal Cancer). The expanded oncology menu is powered in part by Next Generation Sequencing (NGS technology that med fusion validated in the summer of 2014 in its CLIA and CAP accredited laboratory.)
“Cancer is a complex disease of the genome where each tumor has its own set of genetic alterations,” commented Dr. Tom Lohmann, CMO, med fusion. “Increased understanding of the underlying genetic changes that may be driving tumor growth or metastasis can enable precise treatment strategies tailored to the genetic profile of each patient’s cancer.”
“Genomics-based precision medicine requires the clinical interpretation of genomic data – streamlined use of Next Generation Sequencing information in conjunction with other analytic modalities – as well as rules-based decision support,” continued Manuel Glynias, President and CEO of GenomOncology. “The availability of an expert knowledge base like My Cancer Genome, exclusively integrated with the GO Clinical Workbench provides a clinical report that educates physicians and gives them confidence as they make treatment decisions for patients.”
“Our laboratory employs a multi-technology approach to solid tumor profiling in order to present a more complete set of treatment options as defined by the laboratory results,” continued Jon Hart, CEO, med fusion. “Our partnership with GenomOncology combines these laboratory results with the peer-reviewed clinical expertise and clinical trial matching methodology of My Cancer Genome.”
GenomOncology is enabling precision medicine by translating next generation sequencing data into actionable information for clinicians and researchers. In collaboration with molecular pathologists and physicians, GenomOncology has developed the GO Clinical Workbench™, a decision support tool with a step-by-step workflow that takes raw data from the sequencer and translates the specific molecular profile of each patient’s tumor genome into an actionable clinical report. GenomOncology’s research platform, GenomAnalytics™, allows scientists to analyze one or hundreds of genomes simultaneously to look for causal variants, reducing the time required to understand the genomic alterations that lead to new discoveries about the biology of cancer. More information can be found on the company’s website at www.genomoncology.com.
med fusion is a full service laboratory, molecular center of excellence and clinical trials service organization providing support to healthcare providers and biotech/pharmaceutical companies to consistently meet the needs of patients. The full service clinical laboratory includes a dedicated test development and validation team to meet the needs of clients and reference lab services such as pathology and molecular diagnostics. med fusion is committed to facilitate the realization of personalized medicine by specializing in: Oncology, Women’s Health, Urology and Infectious Disease. Headquartered in Lewisville, Texas, med fusion offers their specialized services throughout the U.S. To learn more, please visit www.medfusionservices.com.